Recently, it has been reported that resmetirom (MGL-3196), a selective THR-β agonist designed to improve non-alcoholic steatohepatitis, resulted in a significant reduction in hepatic fat [69]. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.